SCHEMBL14214464

SCHEMBL14214464

CCCCOc1cccc(O[C@@](C)(C=O)CC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR4 O00206 1/20 0.46
TLR2 O60603 1/20 0.46
PLA2G4B P0C869 2/20 0.44
CYP2D6 P10635 3/20 0.43
CYP1A2 P05177 1/20 0.43
MAPK1 P28482 1/20 0.43
CYP2C19 P33261 1/20 0.43
TSHR P16473 1/20 0.43
CACNA1B Q00975 3/20 0.43
KMT2A Q03164 1/20 0.43
THRB P10828 1/20 0.42
LTA4H P09960 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.41
CYSLTR2 Q9NS75 1/20 0.41
CYSLTR1 Q9Y271 1/20 0.41
ACACB O00763 1/20 0.41
ACACA Q13085 1/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14214418 0.80 PPARD (0.38) MAPK1
SCHEMBL13282764 0.79 CACNA1B (0.50) TLR4TLR2PLA2G4BCYP2D6TSHR
SCHEMBL8887829 0.78 KMT2A (0.42) CYP1A2CYP2C19KMT2A
SCHEMBL4397448 0.78 TSHR (0.63) TLR4TLR2PLA2G4BCYP2D6CYP1A2
SCHEMBL6797872 0.76 NPC1 (0.39) MAPK1KMT2ALTA4H
SCHEMBL7345998 0.75 TLR4 (0.52) TLR4TLR2PLA2G4BCYP2D6CYP1A2
SCHEMBL20432126 0.75 TSHR (0.50) TLR4TLR2PLA2G4BCYP2D6CYP1A2
SCHEMBL14214467 0.74 PLA2G4B (0.50) PLA2G4BCYP2D6KMT2ATHRB
1-Butyloxy-3-Propoxybenzene SCHEMBL3390925 0.74 TSHR (0.59) TLR4TLR2PLA2G4BCYP2D6CYP1A2
SCHEMBL12251342 0.73 L3MBTL1 (0.60) TLR4TLR2CYP2D6CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity DR. REDDY'S LABORATORIES LIMITED (IN) 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080114005-A1 2-Methyl-2-{4-[2-(2-methyl-4-oxo-4H-quinazolin-3-yl)-ethylamino]-phenylsulfanyl}-propionic acid ethyl ester; peroxisome proliferaor activated receptors alfa and gamma agonist; diabetic dyslipidemia, metabolic syndrome, diabetes, non-insulin dependent diabetes, cardiovascular disease, and obesity PPARA, PPARD, PPARG TLR4 1242/4885TLR2 736/4885PLA2G4B 604/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.